Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Dermatol. 2010 May-Jun;28(3):337-43. doi: 10.1016/j.clindermatol.2009.06.018.

Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.

Author information

  • 1Department of Dermatology, Second University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy. ada.loschiavo@unina2.it

Abstract

During the last decades, the conventional therapy for autoimmune blistering diseases has been high-dose, long-term systemic corticosteroid and immunosuppressive agents or adjuvant drugs. Long-term, high-dose steroid therapy can result in serious adverse effects. The rationale for using adjuvant drugs is that concerns reducing the need for corticosteroids, and hence, their side effects, or it may result in better control of the disease, or both. Immunosuppressive agents are not free of adverse effects, however. Prolonged immune suppression may account for high rates of morbidity, disability, and possible death. There is no consensus about the first-choice adjuvant drug for the management of blistering autoimmune diseases. This contribution evaluates six adjuvant drugs-cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, intravenous immunoglobulin, and rituximab-and discusses the choice of a "winning drug" that is effective and safe.

Copyright 2010. Published by Elsevier Inc.

PMID:
20541689
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk